bims-maitce Biomed News
on MAIT cells
Issue of 2026–11–15
four papers selected by
Andy E. Hogan, Maynooth University



  1. Sci Adv. 2026 Nov 13. 12(46): eaej0496
      Mucosa-associated invariant T (MAIT) cells have been paradoxically implicated in tissue repair and fibrosis. However, when and how they modulate fibrogenesis in distinct tissue environments remain unclear. Using the carbon tetrachloride model of liver injury in major histocompatibility complex-related protein 1 (MR1)- and MAIT cell-sufficient and -deficient mice, we identify MAIT cells as early drivers of fibrogenesis. MAIT cells exacerbated hepatocellular injury, myofibroblast activation, and matrix deposition during fibrosis initiation, coinciding with rapid polarization toward a MAIT17 phenotype and induction of a profibrotic transcriptional program. Despite acquiring an exhaustion-associated phenotype, MAIT cells retained their effector functions. Mechanistically, MAIT cells limited hepatic regulatory T (Treg) cell accumulation, accompanied by reduced Ki-67 and CXCR3 levels in the latter population. Furthermore, in vivo Treg cell inactivation abrogated MAIT cell-dependent differences in fibrosis severity. Together, these findings identify MAIT cells as early orchestrators of fibrogenesis and reveal a previously unappreciated MAIT-Treg axis that can be therapeutically targeted in the early stages of fibrotic diseases.
    DOI:  https://doi.org/10.1126/sciadv.aej0496
  2. Cardiovasc Res. 2026 Nov 07. pii: cvag274. [Epub ahead of print]
       AIMS: Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes involved in antimicrobial defence and inflammatory regulation, yet their contribution to atherosclerosis remains poorly defined. This study aimed to characterize the distribution, phenotype, and functional role of MAIT cells in human atherosclerotic lesions and complementary murine models.
    METHODS AND RESULTS: MAIT cells were identified using MHC class I-related protein 1 (MR1) tetramers loaded with the agonist 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU). They were significantly enriched among CD3+ T cells in human carotid atherosclerotic plaques compared with matched peripheral blood. Plaque-resident MAIT cells displayed an activated, exhaustion-prone phenotype and a distinct transcriptional profile characterized by upregulation of inflammatory, stress-response, and chemotactic pathways, as revealed by bulk RNA sequencing of purified cells.In murine models, low-density lipoprotein receptor-deficient (Ldlr-/-) mice carrying the CAST locus, which confers increased MAIT cell frequency, exhibited enhanced MAIT cell accumulation in the liver and aorta under a high-cholesterol diet. We identified mature MAIT in the bone marrow which displayed activated state. Moreover, Bulk RNA sequencing of bone marrow-sorted MAIT cells from these mice revealed transcriptional signatures consistent with immune activation and enhanced myelopoiesis. In contrast, MAIT cell-deficient Ldlr-/-CAST MR1-/- mice showed reduced atherosclerotic burden, decreased liver fibrosis, and smaller myocardial infarcts following coronary artery ligation, without changes in plasma cholesterol levels. These protective effects were associated with reduced myeloid progenitors and bone marrow and circulating monocytes, as well as decreased macrophage accumulation within plaques. Importantly, disruption of monocyte mobilization via CCR2 deficiency abrogated MAIT cell-dependent effects, demonstrating a monocyte-mediated mechanism.
    CONCLUSIONS: MAIT cells accumulate in human atherosclerotic plaques and acquire a pro-inflammatory, functionally altered phenotype. Experimental evidence demonstrates that MAIT cells promote atherosclerosis and its complications by enhancing myelopoiesis and monocyte-driven vascular inflammation. These findings identify MAIT cells as previously unrecognized regulators of monocytosis and highlight their potential as therapeutic targets in atherosclerotic cardiovascular disease.
    Keywords:  MAIT cells; atherosclerosis; inflammation; monocytes
    DOI:  https://doi.org/10.1093/cvr/cvag274
  3. Res Sq. 2026 Oct 19. pii: rs.3.rs-10632260. [Epub ahead of print]
      Innate-like T cells are tissue-resident lymphocytes, but the factors that govern their localization to specific tissues, at steady state or after infections, are not well defined. Mucosal-associated invariant T (MAIT) cells are an innate-like T cell population that is relatively frequent in the lungs of mice and humans. Receptor activity-modifying protein 3 (RAMP3) is a member of a family of three proteins that modulate the expression and function of several GPCRs, including those involved in immune responses. Despite this, the role of RAMP3 in T cell immunity has not been widely explored. We found that Ramp3 -/- mice had increased lung MAIT cells at steady-state or after infection, while other T cell populations were less affected. Ramp3 -/- mice had increased surface CXCR6 expression, and RAMP3 overexpression reduced CXCR6. CXCR6 was required for the dramatic increase in lung MAIT cells after infection. These data suggest that RAMP3 negatively regulated CXCR6 and limited lung MAIT cell numbers. This has important consequences, because infected Ramp3 -/- mice had increased IL-17A-secreting lung MAIT cells, but were more susceptible to pulmonary infection, with reduced bacterial clearance, increased cellular infiltration, and immunopathology. The increase in lung MAIT cells after infection occurred predominantly from cells located in the tissue, but in Ramp3 -/- mice there was evidence for some recruitment to the lung. We have established that RAMP3 is a negative regulator of excessive lung MAIT cell responses, acting in part through CXCR6.
    DOI:  https://doi.org/10.21203/rs.3.rs-10632260/v1
  4. Cells. 2026 Oct 25. pii: 1938. [Epub ahead of print]15(21):
      Adoptive T-cell therapy has demonstrated substantial clinical efficacy in several hematological malignancies, but autologous manufacturing remains limited by variability in starting cell material, manufacturing time, product heterogeneity, and T-cell dysfunction. Induced pluripotent stem cells (iPSCs) provide a potentially scalable and genetically engineerable source for the generation of standardized allogeneic T-cell products. This review summarizes current approaches to the differentiation of iPSCs into distinct T-cell phenotypes and evaluates their potential for cancer immunotherapy. We first discuss iPSC-derived conventional αβ T cells, including recent advances in feeder-free and scalable differentiation, maturation, and genetic engineering, as well as preclinical and early clinical evidence. We then examine γδ T cells, invariant natural killer T cells, and mucosal-associated invariant T cells, focusing on their distinctive antigen-recognition mechanisms, effector functions, tissue tropism, differentiation strategies, and therapeutic applications. Across these populations, iPSC technology may facilitate standardized and scalable production while enabling targeted engineering of T-cell specificity and functional properties. However, important challenges remain, including efficient lineage-specific differentiation, maturation, phenotypic consistency, long-term persistence, tumor infiltration, and control of alloreactivity and immunogenicity. Overall, iPSC-derived T cells represent a versatile platform for developing diverse cellular immunotherapies, although their clinical potential remains dependent on further technological and translational advances.
    Keywords:  T cell phenotypes; adoptive cell therapy; induced pluripotent stem cell
    DOI:  https://doi.org/10.3390/cells15211938